Pusineri F, Bini A, Mussoni L, Remuzzi G, Donati M B
J Clin Pathol. 1980 Jul;33(7):631-4. doi: 10.1136/jcp.33.7.631.
Antithrombin-III (AT-III) and factor VIII coagulant (F VIII:C) and antigenic (F VIII:RA) activities have been studied in nine conservatively treated and 26 dialysed uraemic patients. AT-III levels were not significantly different from those of controls in either group. Among dialysed patients, those who had experienced thrombotic occlusions of the vascular accesses could not be distinguished from the remaining patients on the basis of their AT-III levels. Both F VIII:C and F VIII:RA were slightly higher than in controls in conservatively treated patients, but significantly higher in haemodialysed patients, especially in those who had never experienced thrombotic complications of the vascular accesses. No acute changes were observed in either the AT-III or F VIII:C/F VIII:RA ratio in five patients given heparin therapy during a dialytic session or in the interdialytic period. Thus repeated intermittent heparin treatment does not induce a hypercoagulable state in haemodialysed patients.
对9例保守治疗的尿毒症患者和26例透析患者的抗凝血酶III（AT-III）、凝血因子VIII促凝活性（F VIII:C）和抗原活性（F VIII:RA）进行了研究。两组患者的AT-III水平与对照组相比均无显著差异。在透析患者中，发生血管通路血栓闭塞的患者与其余患者在AT-III水平上并无差异。保守治疗患者的F VIII:C和F VIII:RA均略高于对照组，但血液透析患者中这两项指标显著更高，尤其是那些从未发生过血管通路血栓并发症的患者。在透析过程中或透析间期接受肝素治疗的5例患者中，AT-III或F VIII:C/F VIII:RA比值均未观察到急性变化。因此，反复间歇性肝素治疗不会在血液透析患者中诱发高凝状态。
